209 related articles for article (PubMed ID: 21053358)
21. The management of immunosuppression in patients with inflammatory bowel disease and cancer.
Bernheim O; Colombel JF; Ullman TA; Laharie D; Beaugerie L; Itzkowitz SH
Gut; 2013 Nov; 62(11):1523-8. PubMed ID: 23903238
[No Abstract] [Full Text] [Related]
22. Dermal Lesions and Skin Cancer in Patients with Inflammatory Bowel Disease Receiving Immunosuppressive Therapy.
Giagkou E; Saridi M; Albani E; Gaitanis G; Katsanos A; Bechlioulis A; Bacasis AD; Christodoulou DK; Katsanos KH
Asian Pac J Cancer Prev; 2018 Oct; 19(10):2845-2851. PubMed ID: 30362311
[TBL] [Abstract][Full Text] [Related]
23. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease.
Moran GW; Lim AW; Bailey JL; Dubeau MF; Leung Y; Devlin SM; Novak K; Kaplan GG; Iacucci M; Seow C; Martin L; Panaccione R; Ghosh S
Aliment Pharmacol Ther; 2013 Nov; 38(9):1002-24. PubMed ID: 24099467
[TBL] [Abstract][Full Text] [Related]
24. Do inflammatory bowel disease therapies cause cancer?
Mason M; Siegel CA
Inflamm Bowel Dis; 2013 May; 19(6):1306-21. PubMed ID: 23470503
[TBL] [Abstract][Full Text] [Related]
25. A review of heart transplant immunosuppressants and nonmelanoma skin cancer.
Eckembrecher DG; Eckembrecher FJ; Camacho I; Shah H; Dave Y; Patel S; Nouri K
Arch Dermatol Res; 2023 Nov; 315(9):2491-2503. PubMed ID: 37256379
[TBL] [Abstract][Full Text] [Related]
26. Subsequent nonmelanoma skin cancers and impact of immunosuppression in liver transplant recipients.
Funk-Debleds P; Ducroux E; Guillaud O; Ursic-Bedoya J; Decullier E; Vallin M; Euvrard S; Pageaux GP; Boillot O; Dumortier J
J Am Acad Dermatol; 2018 Jul; 79(1):84-91. PubMed ID: 29307647
[TBL] [Abstract][Full Text] [Related]
27. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
Asgari MM; Ray GT; Geier JL; Quesenberry CP
J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
[TBL] [Abstract][Full Text] [Related]
28. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents.
Kwon JH; Farrell RJ
Crit Rev Oncol Hematol; 2005 Oct; 56(1):169-78. PubMed ID: 15979323
[TBL] [Abstract][Full Text] [Related]
29. Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study.
Kopylov U; Vutcovici M; Kezouh A; Seidman E; Bitton A; Afif W
Inflamm Bowel Dis; 2015 Aug; 21(8):1847-53. PubMed ID: 25993693
[TBL] [Abstract][Full Text] [Related]
30. Nonmelanoma skin cancer after renal transplantation: a single-center experience in 1736 transplantations.
Zavos G; Karidis NP; Tsourouflis G; Bokos J; Diles K; Sotirchos G; Theodoropoulou E; Kostakis A
Int J Dermatol; 2011 Dec; 50(12):1496-500. PubMed ID: 21790552
[TBL] [Abstract][Full Text] [Related]
31. Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management.
Lee J; Clarke K
Int J Colorectal Dis; 2015 Dec; 30(12):1595-602. PubMed ID: 26349591
[TBL] [Abstract][Full Text] [Related]
32. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
Borren NZ; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
[TBL] [Abstract][Full Text] [Related]
33. The Complex Interplay Between Inflammatory Bowel Disease and Malignancy.
Kimmel J; Axelrad J
Curr Gastroenterol Rep; 2020 Feb; 22(3):13. PubMed ID: 32056030
[TBL] [Abstract][Full Text] [Related]
34. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment.
Axelrad JE; Lichtiger S; Yajnik V
World J Gastroenterol; 2016 May; 22(20):4794-801. PubMed ID: 27239106
[TBL] [Abstract][Full Text] [Related]
35. Overview on non-melanoma skin cancers in solid organ transplant recipients.
Forchetti G; Suppa M; Del Marmol V
G Ital Dermatol Venereol; 2014 Aug; 149(4):383-7. PubMed ID: 25068224
[TBL] [Abstract][Full Text] [Related]
36. Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study.
Clowry J; Sheridan J; Healy R; Deady S; Keegan D; Byrne K; Cullen G; Mulcahy H; Comber H; Parnell AC; Doherty G; Lally A
J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):978-985. PubMed ID: 28045204
[TBL] [Abstract][Full Text] [Related]
37. Pathogenesis of nonmelanoma skin cancers in organ transplant recipients.
Athar M; Walsh SB; Kopelovich L; Elmets CA
Arch Biochem Biophys; 2011 Apr; 508(2):159-63. PubMed ID: 21232524
[TBL] [Abstract][Full Text] [Related]
38. Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased.
van Schaik FD; van Oijen MG; Smeets HM; van der Heijden GJ; Siersema PD; Oldenburg B
Clin Gastroenterol Hepatol; 2011 May; 9(5):449-50.e1; author reply 450-1. PubMed ID: 21296187
[No Abstract] [Full Text] [Related]
39. Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases.
Solitano V; D'Amico F; Correale C; Peyrin-Biroulet L; Danese S
Br Med Bull; 2020 Dec; 136(1):107-117. PubMed ID: 33200781
[TBL] [Abstract][Full Text] [Related]
40. [Screening for skin cancer in organ transplant recipients in Denmark].
Horn J; Lock-Andersen J; Rasmussen K; Jemec GB
Ugeskr Laeger; 2005 Jun; 167(25-31):2762-5. PubMed ID: 16014261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
